01 June 2011
IMA901 Phase III details presented at ASCO Annual Meeting in Chicag
25 May 2011
immatics presents results of predictive biomarker program at CIMT Meeting
11 April 2011
immatics to receive support from Pfizer for its pivotal Phase III study (IMPRINT) with IMA901, a therapeutic vaccine for advanced renal cell cancer patients
01 March 2011
immatics appoints Dr. Harald Stock to its Board
IMA901 Phase III details presented at ASCO Annual Meeting in Chicag
25 May 2011
immatics presents results of predictive biomarker program at CIMT Meeting
11 April 2011
immatics to receive support from Pfizer for its pivotal Phase III study (IMPRINT) with IMA901, a therapeutic vaccine for advanced renal cell cancer patients
01 March 2011
immatics appoints Dr. Harald Stock to its Board
